AzTrials
AzTrials

Pelvic Organ ProlapseNOVaNCT05812859

Vaginal Orthosis Use After Vaginal Reconstructive Surgery

A study testing Vaginal Orthosis (COSM Medical) in people with Pelvic Organ Prolapse, run by University of Alabama at Birmingham at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A novel vaginal orthosis, or splint, made of silicone will be used daily to help support the healing vaginal reconstruction during the post-operative phase from week 2 to week 12. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Pelvic Organ Prolapse
What is being tested?
Vaginal Orthosis (COSM Medical)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited States
Study dates
29 Jan 2024to 25 Sep 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • POP-Q stage 2 to 4 pelvic organ prolapse
  • Vaginal bulge symptoms as indicated by an affirmative response to either question 4 or 5 of the PFDI:
  • Do you usually have a sensation of bulging or protrusion from the vaginal area?
  • Do you usually have a bulge or something falling out that you can see or feel in the vaginal area?
  • Undergoing reconstructive vaginal surgery for POP-Q stage 2 to 4 pelvic organ prolapse that must include anterior compartment repair and apical suspension.
  • Willing and able to use and self-manage novel vaginal orthosis after POP surgery from 2 weeks post-operative to 12 weeks post-operative.
Show all 9Show fewer
  • Available for 2 and 6 weeks, 3, 6, and 12 months follow-up.
  • Able to complete study assessments, per clinician judgement.
  • Able and willing to provide written informed consent.

Who cannot join

  • Contraindication to surgical intervention as planned in the opinion of the treating surgeon (ie undergoing obliterative procedure).
  • History of previous vaginal reconstructive surgery with or without hysterectomy for POP.
  • Allergy to silicone used in Novel Vaginal Orthosis.
  • Allergy or contraindication to low-dose vaginal estrogen use.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UAB Hospital

    Birmingham, Alabama, 35294

Other trials in United States

About this study

Official title: Novel Vaginal Orthosis for Post-Surgical Healing After Vaginal Reconstructive Surgery For Pelvic Organ Prolapse (NOVa Study)

A novel vaginal orthosis, or splint, made of silicone will be used daily to help support the healing vaginal reconstruction during the post-operative phase from week 2 to week 12.

Read the detailed description

Background/Rationale:

Pelvic Organ Prolapse (POP) is the bulging or herniation of one or more pelvic organs into or out of the vagina. A woman's estimated lifetime risk of POP is 30-50%, with 2-4% of women being symptomatic. Approximately 300,000 women undergo surgical procedures in the United States to repair POP every year. Recurrence rates of POP after native tissue repair utilizing Sacrospinous Ligament Fixation (SSLF) or Uterosacral Ligament Suspension (USLS) vary based on the definition of surgical or anatomic failure used, however a large RCT reports rate of reoperation at 5 years of 8-11.9%.

With the use of the sacrospinous or uterosacral ligaments for apical support, the long axis of the vaginal canal is deflected posteriorly in the pelvis leaving the anterior wall of the vagina vulnerable to receive more of the downward forces produced intra-abdominally during activity and with absolute increases in intra-abdominal pressure. Given this fact, it is not a coincidence that the area of highest recurrence occurs, despite which definition is used, in the anterior vaginal compartment.

Currently, the standard of care for post-operative management in patients who have undergone native tissue pelvic reconstructive surgery is pelvic rest and reduced activity. The Voices for Pelvic Floor Disorders (Voices PFD) in conjunction with the American Urogynecology Society (AUGS) recommend pelvic rest for a minimum of 6 weeks and for activity to "be up and around, but not too active" for the first two weeks, but to increase ambulation and activity as able with guidance from primary surgeon. By the 6-week post-operative visit, most patients are ready to begin to return to normal daily activities, but some may take a longer time-period of reduced activity.

The "wound" healing process following vaginal surgery starts immediately after hemostasis is achieved and the surgery is completed. The first stage is the inflammatory stage, which has rapid onset and reaches maximal reaction within 1-3 days of surgery. This stage is driven by migration of neutrophils and macrophages responding to factors released from the wound site which are responsible for removal of debris and bacteria in order to prepare the site for the second stage of healing, the proliferative stage. The aim of the proliferative stage is to diminish the surgical site tissue area by contraction and fibroplasia, establishing a viable epithelial barrier to activate keratinocytes. This stage is responsible for the closure of the lesion itself, which includes angiogenesis, fibroplasia, and re-epithelialization. These processes begin in the microenvironment of the lesion within the first 48 hours and can unfold up to the 14th day after the onset of the lesion. With the re-epithelization initiated and Type III collagen now deposited, the remodeling stage or wound maturation begins. The ultimate goal of this third and final stage is to restore or achieve the maximal tensile strength of the healing tissue. This is achieved mainly through the degradation of Type III collagen and production of Type 1 collagen.

The objective of this project is to investigate whether patients who have undergone native tissue pelvic reconstructive surgery for POP would benefit from a supportive intravaginal orthotic device. Participants will be fitted for the device at 2 weeks after surgery with daily use continuing until 12 weeks after surgery, thus providing stabilization during the subepithelial wound healing process leading to improved tissue durability and viability along the repaired vaginal walls.

Being tested
Vaginal Orthosis (COSM Medical)
Medical subject headings
Pelvic Organ Prolapse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vaginal Orthosis (COSM Medical)Device

    A vaginal orthosis will be 3-D printed by COSM Medical and provided for patients to use from week 2 through week 12 post-operatively. Device will be placed in morning and removed before bed daily.

Study groups in NCT05812859
Study groupRoleWhat they receive
Device UseExperimentalPatient's will use vaginal orthosis daily from the start of week 2 post-operative to week 12 post-operative.
Receives: Device: Vaginal Orthosis (COSM Medical)
Standard of CareNo interventionPatient's will proceed with normal standard of care post-operative management which is pelvic rest and light acitvity.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective recurrent anterior prolapse

    Pelvic exam will be performed at 12 months post-operative visit and POP-Q measurements will be performed. The "Ba" measurement will be used as the primary outcome comparing the measurements of the vaginal orthosis group and the standard of care group.

    Measured: 12 months.

Secondary outcomes (3)
  1. Subjective recurrent prolapse

    POPDI-6 score will be collected as a part of the PFDI-20 before surgery as well as 3 months, 6 months and 12 months after surgical intervention and change will be compared between groups

    Measured: 12 months

  2. Objective recurrent prolapse

    Other measurements of POP-Q system will be compared between groups

    Measured: 3, 6, and 12 months

  3. Device use complications

    Post-operative complications and adverse events will be compared between groups

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Apr 2023
  2. Study start29 Jan 2024
  3. Primary completion1 Jul 2026
  4. Study completion25 Sep 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05812859
Sponsor's protocol ID
IRB-300010943
Other IDs
Cosm
Acronym
NOVa
Status last verified
Sep 2026
First submitted
31 Mar 2023
Last updated
1 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Vaginal Orthosis (COSM Medical) in people with Pelvic Organ Prolapse, run by University of Alabama at Birmingham at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective recurrent anterior prolapse (time frame: 12 months.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in